Clinical Trial

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study will investigate the efficacy and safety of the combination of pembrolizumab and lenvatinib in PD-L1 positive patients with TKI-resistant EGFR-mutated advanced NSCLC.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-10-02; most recent amendment 2025-07-27.
Status change: Recruiting → Active, Not Recruiting 2025-07-27
Status change: Not Yet Recruiting → Recruiting 2021-12-07
Trial Details
NCT Number NCT05078931
Lead Sponsor Shanghai Chest Hospital
Collaborators: Merck Sharp & Dohme LLC
Conditions NSCLC
Enrollment 35 participants
Start Date 2021-10-27
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-30